Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia-Reference-Cited by-同舟云学术

Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia

Published:2018-06 Issue:6 Volume:22 Page:951-959.e3
ISSN:1934-5909
Container-title:Cell Stem Cell
language:en
Short-container-title:Cell Stem Cell

Author:

Choi Michael Y.,Widhopf George F.,Ghia Emanuela M.,Kidwell Reilly L.,Hasan Md Kamrul,Yu Jian,Rassenti Laura Z.,Chen Liguang,Chen Yun,Pittman Emily,Pu Minya,Messer Karen,Prussak Charles E.,Castro Januario E.,Jamieson Catriona,Kipps Thomas J.

Funder

California Institute of Regenerative Medicine (CIRM)

CIRM Alpha Stem Cell clinic

Moores Cancer Center Specialized Cancer Center Support Grant

UC San Diego Foundation Blood Cancer Research Fund

Koman Family Foundation

Leukemia and Lymphoma Society

NIH

Publisher

Elsevier BV

Subject

Cell Biology,Genetics,Molecular Medicine

Reference52 articles.

1. HTSeq--a Python framework to work with high-throughput sequencing data;Anders;Bioinformatics,2015

2. Andrews, S. (2010). FastQC: a quality control tool for high throughput sequence data (Babraham Bioinformatics).

3. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas;Assou;Stem Cells,2007

4. Analysis of ROR1 protein expression in human cancer and normal tissues;Balakrishnan;Clin. Cancer Res.,2017

5. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors;Ben-Porath;Nat. Genet.,2008

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological management of chronic lymphocytic leukemia: current and emerging therapies;Expert Opinion on Pharmacotherapy;2024-09-08

2. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib;Blood Advances;2024-08-28

3. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia;Expert Review of Hematology;2024-08-21

4. Novel humanized monoclonal antibodies against ROR1 for cancer therapy;Molecular Cancer;2024-08-13

5. Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies;Science China Life Sciences;2024-08-12